TNFSF10 and cancer: Intriguingly, the combination therapy of TQ+TRAIL reported lower IC50 values compared to the standard 5-FU positive anti-cancer drug, which recorded an IC50 value upon MCF-7 cells equal 92.231± 4.61 μM and an IC50 value upon MDA-MB-231 breast cells equal 92.439± 4.62 μM.